Abstract
The COVID-19 pandemic caused by (SARS-CoV-2) a threat, leading to numerous deaths and socioeconomic disruptions. Spurred intense research efforts effective treatment. Our study provides a brief overview COVID-19. Urgent need for effective treatments has prompted extensive research to identify potential drug targets against disease. Review shows most promising drug and their associated therapeutic approaches for combating COVID-19. Key targets include the spike protein, which facilitates viral entry into host cells, and proteases essential for viral replication. Additionally, RNA-dependent RNA polymerase (RdRp) inhibitors have been explored to inhibit viral RNA replication, highlighting their mechanisms of action, potential therapeutic benefits, and challenges in drug development. Host factors, such as the ACE2 receptor and immune response modulators, are also targeted. Combination therapies and overcoming challenges in the drug development are crucial for successful COVID-19 treatment. In this review the molecular docking study is discussed here. The future perspective of drug targets for COVID-19 encompasses a range of innovative approaches aimed at combating the virus and preparing for future outbreaks. The review also discusses the challenges faced and future directions in the field of drug target research for COVID-19. This review will provide an overview of the anticipated advancements in drug target discovery and development for COVID-19, highlighting key areas of focus and potential strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.